Pharmacokinetics of Meropenem in Critically Ill Patients with Acute Renal Failure Treated by Continuous Hemodiafiltration

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1998-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.42.9.2421PMID 9736574PMCID PMC105844
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections.

  1997cited by this paper
• A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.

  1995cited by this paper
• Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

  1995influential reference
• Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.

  1995cited by this paper
• Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.

  1995cited by this paper
• Meropenem: a microbiological overview.

  1995cited by this paper
• Pharmacokinetics of meropenem in patients with intra-abdominal infections

  1994cited by this paper
• Drug Dosage in Patients during Continuous Renal Replacement Therapy

  1993influential reference
• Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease

  1993cited by this paper
• The disposition and metabolic fate of 14C-meropenem in man.

  1993cited by this paper
• Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment

  1992influential reference
• Pharmacokinetics of meropenem in subjects with various degrees of renal impairment

  1992influential reference
• Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I

  1992cited by this paper
• Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.

  1991cited by this paper
• Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males

  1991cited by this paper
• MODFIT: a pharmacokinetics computer program.

  1990cited by this paper
• The disposition and metabolism of meropenem in laboratory animals and man.

  1989cited by this paper
• The pharmacokinetics of meropenem in volunteers.

  1989cited by this paper
• Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

  1988influential reference
• Continuous arteriovenous hemofiltration in acute renal failure.

  1985cited by this paper
• Continuous arteriovenous hemofiltration for acute renal failure.

  1984cited by this paper

• Evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation.

  2025cites this paper
• Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy

  2024cites this paper
• Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations

  2023cites this paper
• Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation

  2021cites this paper
• Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno‐venous haemofiltration

  2021cites this paper
• A meropenem pharmacokinetics model in patients with haematological malignancies.

  2020cites this paper
• Population pharmacokinetic analysis of meropenem in critically ill patients with acute kidney injury treated with continuous hemodiafiltration.

  2020cites this paper
• Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.

  2020cites this paper
• The effect of direct hemoperfusion with polymyxin B immobilized cartridge on meropenem in critically ill patients requiring renal support.

  2019cites this paper
• Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

  2018cites this paper
• Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment

  2018cites this paper
• Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study

  2018cites this paper
• 291 – Pharmacokinetic-Pharmacodynamic Basis of Optimal Antibiotic Therapy

  2018cites this paper
• Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam

  2018cites this paper
• Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections

  2018cites this paper
• A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy

  2018cites this paper
• Scaling beta‐lactam antimicrobial pharmacokinetics from early life to old age

  2018cites this paper
• Antibiotic Dosing in Continuous Renal Replacement Therapy.

  2017cites this paper
• Simple UV Spectrophotometric Method Development for Determination of Meropenem in Bulk Form

  2017cites this paper
• Instructions for use Title Pharmacokinetics and the most suitable regimen of panipenem / beta mipron in critically ill patientsreceiving continuous renal replacement therapy : a pilot study

  2017cites this paper
• Instructions for use Title Pharmacokinetics and the most suitable regimen of panipenem / beta mipron in critically ill patients receiving continuous renal replacement therapy : a pilot study

  2017cites this paper
• Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations

  2016cites this paper
• Pharmacokinetics of Continuous Infusion Meropenem With Concurrent Extracorporeal Life Support and Continuous Renal Replacement Therapy: A Case Report.

  2016cites this paper
• Antibiotic Dosing During Continuous Renal Replacement Therapy (CRRT)

  2016cites this paper
• Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy

  2016cites this paper
• Meropenem Population Pharmacokinetics in Critically Ill Patients with Septic Shock and Continuous Renal Replacement Therapy: Influence of Residual Diuresis on Dose Requirements

  2015cites this paper
• A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics

  2015cites this paper
• How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?

  2015cites this paper
• Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?

  2015cites this paper
• β-lactam antibiotic concentrations during continuous renal replacement therapy

  2014cites this paper
• Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?

  2014cites this paper
• Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy

  2014cites this paper
• The Impact of Variation in Renal Replacement Therapy Settings on Piperacillin, Meropenem, and Vancomycin Drug Clearance in the Critically Ill: An Analysis of Published Literature and Dosing Regimens*

  2014cites this paper
• Meropenem in children receiving continuous renal replacement therapy: Clinical trial simulations using realistic covariates

  2014cites this paper
• Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.

  2014cites this paper
• PDATE ontinuous infusion of iperacillin / tazobactam in patients ith severe infections : A possible harmacokinetic optimisation ? erfusion continue de pipéracilline / tazobactam chez les patients résentant des infections sévères : une optimisation harmacocinétique possible ?

  2014cites this paper
• [Dosage of antipseudomonal antibiotics in patients with acute kidney injury subjected to continuous renal replacement therapies].

  2013cites this paper
• Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.

  2012cites this paper
• Minor Fluctuations in Renal Function May Alter Therapeutic Drug Concentrations Substantially during High-Dose, Continuous-Infusion Beta-Lactam Therapy for Multi-Drug-Resistant Gram-Negative Bacilli

  2012cites this paper
• [Study of factors affecting drug extraction during continuous hemofiltration and hemodiafiltration, and the contribution of extraction to systemic clearance].

  2012cites this paper
• Recommended b-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy

  2011cites this paper
• Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy

  2011cites this paper
• Use of Meropenem by Continuous Infusion to Treat a Patient with a Blakpc-2-Positive Klebsiella pneumoniae Blood Stream Infection

  2011cites this paper
• Antibiotic dosing in critically ill patients with acute kidney injury

  2011cites this paper
• Pharmacokinetics of antibiotics in adults with major burns

  2011cites this paper
• Meropenem, aspectos farmacocinéticos/farmacodinámicos y seguridad

  2010cites this paper
• Principles of Antibacterial Dosing in Continuous Renal Replacement Therapy

  2010cites this paper
• CHAPTER 5 – Antimicrobial agents and the kidneys

  2010cites this paper
• Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration

  2010influential citation
• A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?

  2009cites this paper
• Principles of antibacterial dosing in continuous renal replacement therapy

  2009influential citation
• The Impact of Continuous Renal Replacement Therapy on Drug Therapy

  2009cites this paper
• Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

  2009cites this paper
• Pharmacokinetic and pharmacodynamic properties of meropenem.

  2008cites this paper
• Population Pharmacokinetics of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy

  2008cites this paper
• Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy

  2008cites this paper
• Pharmacokinetic modeling and dosage adaptation of biapenem in Japanese patients during continuous venovenous hemodiafiltration

  2008cites this paper
• In vitro AN69 and Polysulphone Membrane Permeability to Ceftazidime and in vivo Pharmacokinetics during Continuous Renal Replacement Therapies

  2007cites this paper
• Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role.

  2007cites this paper
• Treatment with Tigecycline of Recurrent Urosepsis Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli

  2007cites this paper
• Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit.

  2007cites this paper
• Continuous infusion of β-lactam antibiotics in severe infections: a review of its role

  2007cites this paper
• Quantification of meropenem in plasma and cerebrospinal fluid by micellar electrokinetic capillary chromatography and application in bacterial meningitis patients.

  2007cites this paper
• Case Report: Treatment of Recurrent Urosepsis Caused by ESBL-Producing Escherichia coli with Tigecycline JCM01340-07 – REVISED VERSION

  2007cites this paper
• Case Report: Treatment of Recurrent Urosepsis Caused by ESBL-Producing Escherichia coli with Tigecycline

  2007cites this paper
• Pharmacokinetics and the Most Suitable Regimen of Panipenem/Beta Mipron in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot Study

  2006cites this paper
• Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.

  2005cites this paper
• Meropenem and Continuous Renal Replacement Therapy: In Vitro Permeability of 2 Continuous Renal Replacement Therapy Membranes and Influence of Patient Renal Function on the Pharmacokinetics in Critically Ill Patients

  2005cites this paper
• Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers

  2005cites this paper
• Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.

  2005cites this paper
• Pharmacokinetics of Antibiotics During Continuous Renal Replacement Therapy

  2005cites this paper
• Drug Dosing During Intermittent Hemodialysis and Continuous Renal Replacement Therapy

  2004cites this paper
• Elimination of linezolid by an in vitro extracorporeal circuit model.

  2004cites this paper
• Elimination of Linezolid by an in vitro Extracorporeal Circuit Model

  2004cites this paper
• Correlation of Meropenem Plasma Levels with Pharmacodynamic Requirements in Critically Ill Patients Receiving Continuous Veno-Venous Hemofiltration

  2003cites this paper
• Pharmacokinetics and Dosage Adaptation of Meropenem during Continuous Venovenous Hemodiafiltration in Critically Ill Patients

  2003cites this paper
• Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients.

  2002cites this paper
• Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC.

  2002cites this paper
• Pharmacokinetics of Piperacillin-Tazobactam in Anuric Intensive Care Patients during Continuous Venovenous Hemodialysis

  2002cites this paper
• Meropenem and continuous renal replacement.

  2001cites this paper
• Prescription of Antimicrobial Agents in Patients Undergoing Continuous Renal Replacement Therapy

  2001cites this paper
• Comparative Pharmacokinetics of the Carbapenems

  2000cites this paper
• Meropenem

  2000cites this paper
• Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration

  2000cites this paper
• Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure.

  2000cites this paper
• Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno‐venous hemofiltration or hemodiafiltration

  2000cites this paper
• Meropenem: a review of its use in patients in intensive care.

  2000cites this paper
• Pharmacokinetics of Meropenem in Patients with Renal Failure and Patients Receiving Renal Replacement Therapy

  2000cites this paper
• Elimination of Meropenem by Continuous Hemo(Dia) Filtration: An in Vitro One-Compartment Model

  1999cites this paper